title: Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists.
abstract: The purpose of this study was to investigate the effectiveness of oral treatment with the endothelin (ET) A/B receptor antagonist Ro 47-0203, 4-tert-butyl-N-[6-(hydroxy- ethoxy)-5-(2-methoxy-phenoxy)-2'-bipyrimidin-4-yl]-benzenesulfonam ide (bosentan), and the ET A receptor antagonist 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy- phenyl)-4-oxo-but-2-enoic acid monosodium salt (PD155080), in the prevention of subarachnoid hemorrhage (SAH)-induced delayed cerebral vasospasm. Double hemorrhage in the rabbit constricted the basilar artery to 34% if control as determined by angiography. Oral bosentan and PD155080 administration after the initial SAH decreased the magnitude of constriction to 9% and 16% of control, respectively. Plasma and cerebrospinal fluid bosentan levels and plasma PD155808 levels were consistent with concentrations reported to inhibit ET-1 constriction of blood vessels in vitro. These results support the use of oral administration of ET A/B and ET A receptor antagonists as potential specific treatment for vasospasm resulting from SAH in humans.
authors.affiliation: Department of Neurosurgery, University of Cincinnati, Ohio, USA.
authors.forename: M
authors.initials: M
authors.lastname: Zuccarello
authors.forename: G B
authors.initials: GB
authors.lastname: Soattin
authors.forename: A I
authors.initials: AI
authors.lastname: Lewis
authors.forename: V
authors.initials: V
authors.lastname: Breu
authors.forename: H
authors.initials: H
authors.lastname: Hallak
authors.forename: R M
authors.initials: RM
authors.lastname: Rapoport
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001488:Basilar Artery / Q000187:drug effects / Q000503:physiopathology; D000077300:Bosentan; D004149:Dioxoles / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D065128:Endothelin Receptor Antagonists; D002546:Ischemic Attack, Transient / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D011817:Rabbits; D013345:Subarachnoid Hemorrhage / Q000150:complications* / Q000503:physiopathology; D013449:Sulfonamides / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D004149:Dioxoles; D065128:Endothelin Receptor Antagonists; C093322:PD 155080; D013449:Sulfonamides; D000077300:Bosentan